Full Press Release Details
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) --Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at theEURETINA Innovation Spotlightbeing held as part of the 25thEURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.
Details for the presentations are as follows:
Session:VEGF Related and Other Retinal IndicationsTitle:Optimising the treatment of retinal diseasePresenter:Bob Jahr, Chief Executive Officerof Outlook TherapeuticsDate and Time:Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT
For more information about this event, please visitEIS 2025.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.